Cancer Protein CA125 Blocks Investigational Therapy Farletuzumab’s Anti-Tumor Effectiveness, Study Finds

Cancer Protein CA125 Blocks Investigational Therapy Farletuzumab’s Anti-Tumor Effectiveness, Study Finds
The protein CA125, which is commonly expressed on the surface of ovarian cancer cells and is secreted into the bloodstream, was found to block the activity of investigational drug farletuzumab. Farletuzumab is currently in clinical development for the treatment of ovarian cancer. This process was described in the preclinical study, “Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc receptor engagement,” published in the journal Oncotargetaccording to a statement from the therapy’s developer. Farletuzumab, also known as MORAb-003, is an antibody developed by Eisai subsidiary Morphotek to specifically target the folate receptor alpha (FRA), which is almost entirely absent in normal cells but highly expressed in several cancers, including ovarian, endometrial, and breast cancers. After binding to the target cells by their FRA receptor, farletuzumab then activates immune cells to recognize a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *